Population pharmacokinetics of gemcitabine and its metabolite in japanese cancer patients: Impact of genetic polymorphisms

Clinical Pharmacokinetics

Volumn 49, Issue 8, 2010, Pages 549-558

  Sugiyama, Emiko ^a   Kaniwa, Nahoko ^a   Kim, Su Ryang ^a   Hasegawa, Ryuichi ^a   Saito, Yoshiro ^a   Ueno, Hideki ^b   Okusaka, Takuji ^b   Ikeda, Masafumi ^b   Morizane, Chigusa ^b   Kondo, Shunsuke ^b   Yamamoto, Noboru ^b   Tamura, Tomohide ^b   Furuse, Junji ^c   Ishii, Hiroshi ^c   Yoshida, Teruhiko ^d   Saijo, Nagahiro ^c   Sawada, Jun Ichi ^e  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

Author keywords

antineoplastics; gemcitabinepharmacokinetics; genetic polymorphism; genotype; metabolites; pharmacokinetic modelling; pharmacokinetics; population pharmacokinetics

Indexed keywords

2',2'-DIFLUORO-2'-DEOXYURIDINE; ANTINEOPLASTIC ANTIMETABOLITE; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLOXURIDINE; GEMCITABINE; SLC29A1 PROTEIN, HUMAN;

ADULT; AGED; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; COMPARATIVE STUDY; COMPUTER SIMULATION; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; MIDDLE AGED; NEOPLASMS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ASIAN CONTINENTAL ANCESTRY GROUP; COMPUTER SIMULATION; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; FLOXURIDINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77954520138     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11532970-000000000-00000     Document Type: Article

References (27)

1. Noble S, Goa KL. Gemcitabine: a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997; 54: 447-472
2. Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab 2004; 32: 63-84
3. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58 (19): 4349-4357
4. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995; 6: S7-13
5. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2,2-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988; 48 (14): 4024-4031
6. Kiani A, Kohne CH, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol 2003; 51: 266-270
7. Aapro MS, Martin C, Hatty S.Gemcitabine: asafety review. Anticancer Drugs 1998; 9: 191-201
8. Gallelli L, Nardi M, Prantera T, et al. Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer. Pharmacol Res 2004; 49: 259-263
9. Locker GJ, Wenzel C, Schmidinger M, et al. Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. Anticancer Drugs 2001; 12: 209-212
10. Sauer-Heilborn A, Kath R, Schneider CP, et al. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol 1999; 125: 637-640
11. Mercier C, Raynal C, Dahan L, et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase down-regulation. Pharmacogenet Genomics 2007; 17: 841-844
12. Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25: 32-42
13. Yonemori K, Ueno H, Okusaka T, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005; 11: 2620-2624
14. Ueno H, Kaniwa N, Okusaka T, et al. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 2009; 100 (6): 870-873
15. Kim SR, Saito Y, Maekawa K, et al. Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet 2008; 23 (5): 379-384
16. Kim SR, Saito Y, Maekawa K, et al. Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab Pharmacokinet 2006; 21: 248-256
17. De Pas T, De Braud F, Danesi R, et al. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2000; 11: 821-827
18. Hooker AC, Staats CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007; 24: 2187-2197
19. Shi JY, Shi ZZ, Zhang SJ, et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004; 14 (11): 759-768
20. Lamba JK, Crews K, Pounds S, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007; 323 (3): 935-945
21. Jiang X, Galettis P, Links M, et al. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. Br J Clin Pharmacol 2008; 65: 326-333
22. Tham LS, Wang LZ, Soo RA, et al. Does saturable formation of gemcitabine triphosphate occur in patients? Cancer Chemother Pharmacol 2008; 63: 55-64
23. Giovannetti E, Laan AC, Vasile E, et al. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008; 27: 720-725
24. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 1797-1803
25. Tsujie M, Nakamori S, Nakahira S, et al. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res 2007; 27: 2241-2249
26. Nakahira S, Nakamori S, Tsujie M, et al. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res 2008; 28: 179-186
27. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1997; 9: 491-498